Optimal targeting of HER2-PI3K signaling in breast cancer: Mechanistic insights and clinical implications

Abstract

The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2+ breast cancer by inhibiting HER2-PI3K-FOXO-survivin signaling. In this review the potential clinical implications of these findings are discussed. © 2013 American Association for Cancer Research.